For research use only. Not for human consumption. Content on this site is for laboratory research and educational reference. Not for human or veterinary use.
Research peptide reference

Peptide research, documented.

Compound overviews and a regulatory tracker built on primary sources. Written for laboratory researchers. No hype, no health claims. For research use only. Not for human consumption.

  • Regulatory items link to sources
  • 12 compounds indexed
  • Dated regulatory updates
Latest research & news

From the research desk

Regulatory developments and method explainers. News items link to their source. For research use only. Not for human consumption.

RegulatoryPrimary source

HHS publishes interim enforcement discretion policy for 503A compounding of six peptides

The policy announced in that notice covers state-licensed pharmacies, federal facilities, and licensed physicians compounding BPC-157, TB-500, Epitalon, Semax, KPV, and MOTS-c under patient-specific prescriptions while the 503A bulks list goes through rulemaking. HHS states that compounded drugs are not FDA-approved. The policy concerns pharmacy compounding, not research-use materials. For research use only. Not for human consumption.

Source: Federal Register, 91 FR 68526 · BakerHostetler analysis

Articles coming soon

Method explainers will be added after editorial review.

Compound index

Research compounds

Structural and regulatory reference for each compound: class, sequence type, and nomenclature. No usage guidance. For research use only. Not for human consumption.

Synthetic peptidePCAC 2026BPC-157Synthetic pentadecapeptide (15 amino acids).
Fragment / analogPCAC 2026TB-500Synthetic peptide related to a fragment of thymosin β4.
Peptide–metal complexGHK-CuCopper(II) complex of the tripeptide Gly-His-Lys.
Fragment / analogPCAC 2026KPVTripeptide (Lys-Pro-Val), the C-terminal sequence of α-MSH.
Mitochondrial-derived peptidePCAC 2026MOTS-c16-amino-acid peptide encoded in mitochondrial DNA.
Synthetic peptidePCAC 2026EpitalonSynthetic tetrapeptide (Ala-Glu-Asp-Gly).
Fragment / analogPCAC 2026SemaxSynthetic heptapeptide derived from an ACTH fragment.
Fragment / analogSelankSynthetic heptapeptide analog of tuftsin.
Synthetic peptideThymosin α128-amino-acid peptide; also listed as TA-1.
Synthetic peptideIpamorelinSynthetic pentapeptide.
Coenzyme (non-peptide)NAD+Nicotinamide adenine dinucleotide, a dinucleotide coenzyme.

“PCAC 2026” marks compounds reviewed at the July 2026 FDA Pharmacy Compounding Advisory Committee meeting. That review concerns pharmacy compounding only. It does not indicate approval or authorize human use of research materials.

COA library

Lot records

Lot records coming soon. A published certificate will be matched to one lot number. For research use only. Not for human consumption.

  1. Lot number

    A published record uses one lot number.

  2. Testing laboratory

    A certificate names the laboratory and the identity and purity methods it reports.

  3. Certificate

    The entry includes the lab name and the test date printed on the certificate.

  4. Lot match

    The lot number on the certificate is the number used to find that record.

Recent lot records

No records published yet.

Sourcing (RUO) links to Peak Amino Labs, which shares ownership with this site.

For research use only. Not for human consumption. Not for human or veterinary use. Not a drug, food, cosmetic, or dietary supplement.

Regulatory tracker

Where things stand

Dated entries, each linked to the agency document or reporting it rests on. Last reviewed . For research use only. Not for human consumption.

  1. Oct 30, 2026

    HHS interim enforcement discretion policy (503A)

    HHS announced it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding with six listed peptide bulk substances, subject to conditions that include a patient-specific prescription and an FDA-registered manufacturer in compliance with CGMP. HHS states the policy is interim and non-binding, and that compounded drugs are not FDA-approved. According to legal analysis, it does not apply to 503B outsourcing facilities or to products sold as research chemicals.

    Federal Register notice (91 FR 68526)BakerHostetler summary

  2. Jul 23–24, 2026

    FDA Pharmacy Compounding Advisory Committee vote

    The committee recommended adding BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax to the 503A bulks list and declined to recommend emideltide. The BPC-157 vote was 8–6 with one abstention. FDA's own briefing document had proposed that BPC-157 not be included. Committee votes are non-binding.

    FDA briefing documentABC News: BPC-157 voteABC News: full outcome

  3. Ongoing

    503A bulks list rulemaking

    FDA may propose adding some or all of these peptides to the 503A bulks list in future rulemaking. We'll add each step here when it's published.

    Federal Register background

About & methodology

How we publish

Peak Amino Research is a reference for laboratory researchers. We publish what can be sourced and leave out what can't.

Primary sources first

News entries link to the agency document, docket or journal article. Secondary reporting is labeled as such.

No health claims

We don't publish dosing, protocols, human-use guidance, or claims of benefit. Compound pages describe structure, nomenclature and regulatory status.

Dated and reviewed

Every page shows when it was last reviewed. Regulatory entries are dated to the source's publication date.

Corrections

Found an error? Email corrections@peakaminoresearch.com. Corrections are noted on the page.

Disclosure: Peak Amino Research is published by the team behind Peak Amino Labs. Links to Peak Amino Labs are marked “Sourcing (RUO).” Editorial content isn't paid for by any third party. Peak Amino Research and Peak Amino Labs share common ownership.